Loading patent…
AssigneesGlaxoSmithKline Intellectual Property Limited, GlaxoSmithKline Intellectual Property Management Limited
InventorsRobert Brian HENDERSON, Jeremy SOKOLOVE, André VAN MAURIK
Estimating the term…
The present disclosure relates to a B lymphocyte Stimulator (BlyS; B-cell activating factor; BAFF) antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC). Also disclosed is a BlyS antagonist for use in the treatment of an autoimmune condition induced following a viral infection. Such autoimmune conditions may be chronic, such as Long Covid. Also provided is a method for the treatment of an autoimmune condition induced following a viral infection comprising administering to a subject in need thereof a therapeutically effective amount of a BlyS antagonist.
A BlyS antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC).
The Blys antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC) which results from infection with the human coronavirus SARS-COV-2.
A method of treating Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC) in a human comprising the steps of:
Dependencies are inferred from the claim text.